Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company, which is focused on advancing a pipeline of potential therapies for patients with unmet medical needs. The Company has clinical programs at various stages of development, and active discovery efforts in oncology and neurological disease. Its pipeline includes EIK1001 TLR7/8 Melanoma, EIK1001 TLR7/8 NSCLC, EIK1003 PARP1, EIK1004 PARP1, EIK1005 WRN Phase 1, EIK1006, and AR-V7. EIK1001 is a systemically administered dual-agonist of toll-like receptors 7 and 8 that has demonstrated single-agent activity, as well as activity in combination with anti-PD-(L)1 agents, across multiple solid tumor types in Phase 1 trials. EIK1003 targets PARP1, a central component of DNA repair machinery in normal cells. EIK1003 is being evaluated in a Phase 1/2 study of patients with breast, ovarian, or prostate malignancies that have known or suspected deleterious mutations of select homologous recombination repair (HRR) genes.